Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun;299(3):111-38.
doi: 10.1007/s00403-007-0744-y. Epub 2007 May 12.

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

A Nast  1 , I Kopp, M Augustin, K B Banditt, W H Boehncke, M Follmann, M Friedrich, M Huber, C Kahl, J Klaus, J Koza, I Kreiselmaier, J Mohr, U Mrowietz, H M Ockenfels, H D Orzechowski, J Prinz, K Reich, T Rosenbach, S Rosumeck, M Schlaeger, G Schmid-Ott, M Sebastian, V Streit, T Weberschock, B Rzany
Affiliations
Review

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

A Nast et al. Arch Dermatol Res. 2007 Jun.

Abstract

Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de ).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overview of the therapeutic options evaluated for chronic plaque psoriasis (the therapeutic options are listed alphabetically and do not represent a ranking)
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10495380', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10495380/'}]}
    2. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE (1999) Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41(4):581–583 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1046/j.1365-2133.1996.d01-1035.x', 'is_inner': False, 'url': 'https://doi.org/10.1046/j.1365-2133.1996.d01-1035.x'}, {'type': 'PubMed', 'value': '8915141', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8915141/'}]}
    2. Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 135(4):533–537 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00105-005-0906-9', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00105-005-0906-9'}, {'type': 'PubMed', 'value': '15711815', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15711815/'}]}
    2. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U (2005) Psychosoziale Folgen der Psoriasis—eine empirische Studie über die Krankheitslast bei 3753 Betroffenen. Hautarzt 56(5):466–472 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0190-9622(99)70112-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0190-9622(99)70112-x'}, {'type': 'PubMed', 'value': '10459113', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10459113/'}]}
    2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1): 401–407 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1046/j.1087-0024.2003.09102.x', 'is_inner': False, 'url': 'https://doi.org/10.1046/j.1087-0024.2003.09102.x'}, {'type': 'PubMed', 'value': '15083780', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15083780/'}]}
    2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 9(2):136–139 - PubMed

MeSH terms

Substances